anoth cut earn stay
posit post
preview lower est challeng
last week pre-releas result rescind guid link came
better expect larg due holx lower exposur china japan vs
med-tech diagnost dx peer howev given recent commentari
med-tech compani elect procedur mani estim declin rang
likelihood recess slower expect recoveri
deferr volum believ near-term impact would larger forecast
could downward pressur well lower est
ahead formal earn continu expect qtrli contribut
holx assay like enough off-set broader
relat end-market headwind estim holx rev tie
deferr visit forecast organ sale
base new est lower po detail
remain posit
despit sharpli reduc sale earn outlook peer investor seem will
look beyond near-term impact especi compani involv
test suppli chain immedi crisi pass see
potenti higher level spend dx equip help drive
addit panther placement moreov examin holx overal portfolio
believ key end mkt significantli shift wake
pandem play import role assur women health
situat remain fluid view key question magnitud
period time deferr procedur capit spend come back
quarantin lift sooner expect may see less sever impact
result forecast see tabl reiter buy rate
given attract valuat trade new est vs holx
med-tech dx peer strong balanc sheet per liquid analysi upsid
potenti lead sustain viral test better panther placement
net dbt
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lead manufactur medic
devic product focus heathcar need
mammographi breast biopsi earli stage
treatment remov uterin fibroid
core mammographi diagnost
busi deliv solid perform
believ steadier
foot organ growth upsid due
expand offer breast health strength
molecular diagnost mdx busi cynosur
cyno busi divest thu longer
controversi stock may allow
stock rerat investor focu
tabl revenu mix busi segment geographi estim durat impact
durat social isol stay-at-hom action
ep est vs prior per recent
liquid analysi note liquid analysi life scienc tool diagnost
anim april believ face credit issu even
lower forecast base new forecast lower po
base unchang calendar ep estim roughli line
three-year histor averag compani diagnost med-tech
peer multipl
po base approxim calendar ep estim
roughli line three-year histor averag compani
diagnost med-tech peer multipl believ multipl justifi
given organ growth profil breast molecular diagnost
upsid risk po faster growth core diagnost mammographi
gynecolog surgeri end market synergi addit tuck-in deal
downsid risk po competit pressur slower uptak reimburs
new product market challeng relat pandem unfavor
chang clinic practic guidelin manag departur regulatori risk
faster declin legaci busi
ivi herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
